Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.
Anima Biotech technology uses state-of-the-art molecular biology that can illuminate the protein synthesis process and identify small molecules that regulate mRNA translation.
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
